Navigation Links
Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Date:10/11/2007

Complete Data to be Submitted for Presentation at 2007 San Antonio Breast

Cancer Symposium

REDWOOD CITY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced encouraging results from a study of Oncotype DX in postmenopausal women with node-positive, hormone receptor positive breast cancer conducted by the Southwest Oncology Group (SWOG), a National Cancer Institute clinical trials cooperative group. Oncotype DX is a multi-gene expression test that physicians currently use to predict the likelihood of recurrence and the likelihood of chemotherapy benefit for women with estrogen receptor positive, node-negative breast cancer. This study focused on a different population of patients and results suggest the Oncotype DX test may be useful in predicting survival without recurrence and the benefit of chemotherapy for node-positive breast cancer patients.

For this study, researchers analyzed tumor samples from patients in the SWOG/ Breast Cancer Intergroup of North America trial that evaluated postmenopausal patients with node-positive, hormone receptor positive breast cancer who were treated with chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, followed by tamoxifen) versus tamoxifen alone. Benefit of the addition of chemotherapy was observed in patients with high Oncotype DX Recurrence Scores. However, chemotherapy did not appear to benefit patients with low Oncotype DX Recurrence Scores, despite the presence of positive nodes. These results may be clinically useful in some patients with hormone receptor positive, node-positive breast cancer.

SWOG and Genomic Health plan to submit these data for presentation at the 30th Annual San Antonio Breast Cancer Symposium, December 12 - 16.

About Oncotype DX(TM)

Oncotype DX is the first multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of breast cancer recurrence, the likelihood of breast cancer survival and the likelihood of chemotherapy benefit in women with estrogen receptor-positive, node-negative, tamoxifen-treated breast cancer. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 2,600 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. As of June 30, 2007, over 6,000 physicians have ordered a cumulative total of more than 33,000 tests and the test is now covered by reimbursement contracts and agreements with health plans covering approximately 145 million lives. For more information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the findings suggesting that Oncotype DX predicts disease-free survival and the benefit of chemotherapy in some node-positive patients, the potential clinical utility of our test in some node-positive patients, and our plans to submit the data from this study at the 2007 San Antonio Breast Cancer Symposium. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to: the applicability of clinical results to actual outcomes; our ability to increase usage of our tests; the risk that we may not obtain or maintain sufficient levels of reimbursement for our existing tests and any future tests we may develop; the risks and uncertainties associated with the regulation of our test by FDA; our ability to obtain capital when needed; our history of operating losses; the results of clinical studies and the other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: Genomic Health, the Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference
2. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
3. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
4. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
5. Nationwide MRSA Prevalence Study to Demonstrate Full Scope of Superbug Threat Facing U.S. Healthcare Facilities and Patients
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
8. Antidepressant Use May Boost Fracture Risk, From Harvard Womens Health Watch
9. FDLI 50th Annual Meeting Heralds New ERA in Healthcare Innovations, FDA Regulations
10. New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory Properties and Increased Health Benefits
11. Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... , Aug. 10, 2017  Physical Rehabilitation Network (PRN), acquired ... Lakewood, Colorado . The reputable clinic will ... , PT, DPT with his staff of four clinicians. Lipkin ... Pittsburgh and brings over 10 years of experience with a ... Belmar PT marks the 10th PRN clinic in and around ...
(Date:8/7/2017)... Aug. 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2017. The ... or about October 27, 2017 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
(Date:8/4/2017)... , Aug. 4, 2017 The search for ... after a physician/patient consult has long been the goal ... a notable focus of the largest meeting of lab ... to healthcare market research firm Kalorama Information.  The firm ... (POCT) offerings or related supplies and software were at ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... The ... a three-year grant totaling $975,000, renewing its funding from the Health Resources and ... , This funding marks, the fourth time the HRSA administration has renewed its ...
(Date:8/16/2017)... Linda, Ca (PRWEB) , ... August 16, 2017 , ... ... innovators, engineers, and scientists from around the world, is excited to announce Andrew Ly ... him in his academic pursuits, covering textbook costs. , Ly, who is in ...
(Date:8/16/2017)... ... , ... With a new PD diagnosis every nine minutes, research is critical ... are awarded through a competitive application process and reviewed by APDA’s Scientific Advisory Board ... in all areas relevant to PD research. The SAB meets annually to review ...
(Date:8/16/2017)... ... , ... Melbourne’s reign as the world’s most liveable city has been extended ... Index. , The Index surveys 140 of the world’s cities and Melbourne has come ... come in the top three of the index. So what is it that keeps ...
(Date:8/16/2017)... ... August 16, 2017 , ... Harbor Retirement ... Beach, announced today that two of their associates were recognized with individual “Best ... senior living communities in Florida. The awards were announced at the 5th Annual ...
Breaking Medicine News(10 mins):